Anatomical Therapeutic Chemical (ATC) Classification

[ Brite menu | Download htext | Download json | Help ]
Search

1st Level  2nd Level  3rd Level  4th Level  5th Level  6th Level 

 A ALIMENTARY TRACT AND METABOLISM
 
 B BLOOD AND BLOOD FORMING ORGANS
 
 C CARDIOVASCULAR SYSTEM
 
 D DERMATOLOGICALS
 
 G GENITO URINARY SYSTEM AND SEX HORMONES
 
 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
 
 J ANTIINFECTIVES FOR SYSTEMIC USE
 
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
   L01 ANTINEOPLASTIC AGENTS
     L01A ALKYLATING AGENTS
     L01B ANTIMETABOLITES
     L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
     L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
     L01E PROTEIN KINASE INHIBITORS
       L01EA BCR-ABL tyrosine kinase inhibitors
       L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
       L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
       L01ED Anaplastic lymphoma kinase (ALK) inhibitors [DG:DG03136]
       L01EE Mitogen-activated protein kinase (MEK) inhibitors [DG:DG03137]
       L01EF Cyclin-dependent kinase (CDK) inhibitors [DG:DG03138]
       L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
       L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
       L01EJ Janus-associated kinase (JAK) inhibitors
       L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
       L01EL Bruton's tyrosine kinase (BTK) inhibitors [DG:DG02022]
       L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors [DG:DG03139]
       L01EX Other protein kinase inhibitors
         L01EX01 Sunitinib [DG:DG00712]
         L01EX02 Sorafenib [DG:DG00713]
           D08524  Sorafenib (USAN/INN)
           D06272  Sorafenib tosylate (USAN) <JP/US>
         L01EX03 Pazopanib
         L01EX04 Vandetanib
         L01EX05 Regorafenib [DG:DG00720]
         L01EX06 Masitinib
         L01EX07 Cabozantinib [DG:DG01670]
         L01EX08 Lenvatinib [DG:DG01362]
         L01EX09 Nintedanib [DG:DG01374]
         L01EX10 Midostaurin
         L01EX11 Quizartinib [DG:DG01364]
         L01EX12 Larotrectinib [DG:DG02923]
         L01EX13 Gilteritinib [DG:DG01948]
         L01EX14 Entrectinib
         L01EX15 Pexidartinib [DG:DG02960]
         L01EX16 Erdafitinib
         L01EX17 Capmatinib [DG:DG02081]
         L01EX18 Avapritinib
         L01EX19 Ripretinib
         L01EX20 Pemigatinib
         L01EX21 Tepotinib [DG:DG03087]
     L01X OTHER ANTINEOPLASTIC AGENTS
   L02 ENDOCRINE THERAPY
   L03 IMMUNOSTIMULANTS
   L04 IMMUNOSUPPRESSANTS
 
 M MUSCULO-SKELETAL SYSTEM
 
 N NERVOUS SYSTEM
 
 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
 
 R RESPIRATORY SYSTEM
 
 S SENSORY ORGANS
 
 V VARIOUS

[ DRUG | BRITE | KEGG2 | KEGG ]
Last updated: December 14, 2020
According to WHO's ATC 2021

» Japanese version